*Refresh the page if the below document does not appear.
Rel Life Sciences secured $2.5 billion investment
Mukesh Ambani-owned Reliance Life Sciences has set aside Rs 2,500 crore over the next two years for the development of novel gene therapies and vaccines, as well as capacity expansion.
Biocon impacted by numerous 483s
The largest biopharmaceutical company in India, Biocon, has disclosed that the USFDA has issued three Form 483s as a result of inspections of the Biocon Biologics division’s manufacturing facilities.
Illegal drug factory manufacturing fake drugs halted in Baddi, Himachal
Drug Control Administration officials found an illegal drug factory at Baddi on Thursday night that was producing fake drugs. Arya Pharma was granted a licence by the FSSAI that allowed it to manufacture only nutraceuticals
NACO resumes one-month HIV medication distribution across the country
Union Ministry of Health and Family Welfare intervened, and the National AIDS Control Organization (NACO) has since resumed dispensing HIV medications for one month across the country.
Boehringer Ingelheim earned its first FDA nod in dermatology
The world’s largest privately held pharma company became the first to receive FDA approval to treat generalised pustular psoriasis (GPP), a rare and potentially fatal skin condition characterised by painful blister eruptions.
Zydus Lifesciences & Lupin recalled products in US market due to manufacturing issues
Due to manufacturing problems, domestic pharmaceutical companies Zydus Lifesciences and Lupin are recalling goods in the US, which is the world’s largest market for pharmaceuticals.
Findings from phase III cardiovascular outcomes study included on Bayer's Kerendia's updated label in US
USFDA granted Bayer permission to update
Kerendia’s label to reflect the results of the
phase III FIGARO-DKD cardiovascular
outcomes study in people with type 2 diabetes
and chronic kidney disease (CKD) (T2D).
